ReviewInternational journal of molecular sciences2020
Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 114 citations in OpenAlex.
- Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.BMC cancer · 2024Trial
- Identifying PLAU as a shared pathogenic gene in type 2 diabetes and bladder urothelial carcinoma through integrated transcriptomic analysis and machine learning for diagnostic and therapeutic value.Clinical and experimental medicine · 2026Article
- Effect of Epigallocatechin-3-Gallate on Depression-Related Cytokines in Thalassemia Patients: Molecular and Cellular Evaluation.Journal of clinical laboratory analysis · 2026Article
- Article
- Comparative Analysis of the Effects of Mogroside V, Epigallocatechin Gallate, and Resveratrol on Growth Performance, Blood Parameters, Rumen Microbiota, and Short-Chain Fatty Acid Metabolism in Heat-Stressed Hu Sheep.Food science & nutrition · 2026Article
- Solid-State Nanopore Single-Molecule Analysis of SARS-CoV-2 N Protein: From Interaction Exploration to Small-Molecule Antagonism.Sensors (Basel, Switzerland) · 2025Article
- Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by COVID-19 infection in lung cancer.Precision radiation oncology · 2025Article
- Liupao tea aqueous extract alleviates dextran sulfate sodium-induced ulcerative colitis in rats by modulating the gut microbiota.Open life sciences · 2025Article
- COVID-19 Humic/Fulvic Acid Plus Epigallocatechin Gallate Treatment: A Retrospective Chart Review.Cureus · 2025Article
- Exploring the Potential of Epigallocatechin Gallate in Combating Insulin Resistance and Diabetes.Nutrients · 2024Article
- Recommendations and guidelines of integrative medicine for COVID-19 care: The APEC project outcome.Integrative medicine research · 2024Article
- Alleviation effects of epigallocatechin-3-gallate against acute kidney injury following severe burns.Clinical and experimental nephrology · 2024Article
- Dual action of epigallocatechin-3-gallate in virus-induced cell Injury.Journal, genetic engineering & biotechnology · 2023Article
- Article
- The Therapeutic Potential of Natural Dietary Flavonoids against SARS-CoV-2 Infection.Nutrients · 2023Review
- COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way.Bioscience reports · 2023Review
- Liposomes Loaded with Green Tea Polyphenols-Optimization, Characterization, and Release Kinetics Under Conventional Heating and Pulsed Electric Fields.Food and bioprocess technology · 2023Article
- The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Green Tea Consumption and the COVID-19 Omicron Pandemic Era: Pharmacology and Epidemiology.Life (Basel, Switzerland) · 2023Article
- Discovery of Polyphenolic Natural Products as SARS-CoV-2 MPharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some coronavirus disease 2019 (COVID-19) patients develop acute pneumonia which can result in a cytokine storm syndrome in response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection. The most effective anti-inflammatory drugs employed so far in severe COVID-19 belong to the cytokine-directed biological agents, widely used in the management of many autoimmune diseases. In this paper we analyze the efficacy of epigallocatechin 3-gallate (EGCG), the most abundant ingredient in green tea leaves and a well-known antioxidant, in counteracting autoimmune diseases, which are dominated by a massive cytokines production. Indeed, many studies registered that EGCG inhibits signal transducer and activator of transcription (STAT)1/3 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factors, whose activities are crucial in a multiplicity of downstream pro-inflammatory signaling pathways. Importantly, the safety of EGCG/green tea extract supplementation is well documented in many clinical trials, as discussed in this review. Since EGCG can restore the natural immunological homeostasis in many different autoimmune diseases, we propose here a supplementation therapy with EGCG in COVID-19 patients. Besides some antiviral and anti-sepsis actions, the major EGCG benefits lie in its anti-fibrotic effect and in the ability to simultaneously downregulate expression and signaling of many inflammatory mediators. In conclusion, EGCG can be considered a potential safe natural supplement to counteract hyper-inflammation growing in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.